Tokushima University / Educator and Researcher Directory --- Funamoto, Masafumi

Personal Web Page

https://researchmap.jp/funamoto-masafumi (researchmap)

Field of Study

○	Life sciences [Pharmacology]
○	Life sciences [Cardiology]
○	Life sciences [Molecular biology]

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Steeve Akumwami, Asadur Rahman, Masafumi Funamoto, Akram Hossain, Asahiro Morishita, Yasumasa Ikeda, Hiroaki Kitamura, Kento Kitada, Takahisa Noma, Yuichi Ogino and Akira Nishiyama : Effects of D-Allose on experimental cardiac hypertrophy., Journal of Pharmacological Sciences, Vol.156, No.2, 142-148, 2024. (Summary) The hallmark of pathological cardiac hypertrophy is the decline in myocardial contractility caused by an energy deficit resulting from metabolic abnormalities, particularly those related to glucose metabolism. Here, we aim to explore whether D-Allose, a rare sugar that utilizes the same transporters as glucose, may restore metabolic equilibrium and reverse cardiac hypertrophy. Isolated neonatal rat cardiomyocytes were stimulated with phenylephrine and treated with D-Allose simultaneously for 48 h. D-Allose treatment resulted in a pronounced reduction in cardiomyocyte size and cardiac remodelling markers accompanied with a dramatic reduction in the level of intracellular glucose in phenylephrine-stimulated cells. The metabolic flux analysis provided further insights revealing that D-Allose exerted a remarkable inhibition of glycolysis as well as glycolytic capacity. Furthermore, in mice subjected to a 14-day continuous infusion of isoproterenol (ISO) to induce cardiac hypertrophy, D-Allose treatment via drinking water notably reduced ISO-induced cardiac hypertrophy and remodelling markers, with minimal effects on ventricular wall thickness observed in echocardiographic analyses. These findings indicate that D-Allose has the ability to attenuate the progression of cardiomyocyte hypertrophy by decreasing intracellular glucose flux and inhibiting glycolysis. (Keyword) Animals / Cardiomegaly / Myocytes, Cardiac / Glycolysis / Isoproterenol / Glucose / Phenylephrine / male / Cells, Cultured / Mice, Inbred C57BL / Rats / knockout mice / Disease Models, Animal / Rats, Sprague-Dawley (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jphs.2024.08.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39179333 ● Search Scopus @ Elsevier (PMID): 39179333 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jphs.2024.08.002 (DOI: 10.1016/j.jphs.2024.08.002, PubMed: 39179333)
2.	Yasufumi Katanasaka, Harumi Yabe, Noriyuki Murata, Minori Sobukawa, Yuga Sugiyama, Hikaru Sato, Hiroki Honda, Yoichi Sunagawa, Masafumi Funamoto, Satoshi Shimizu, Kana Shimizu, Toshihide Hamabe-Horiike, Philip Hawke, Maki Komiyama, Kiyoshi Mori, Koji Hasegawa and Tatsuya Morimoto : Fibroblast-specific PRMT5 deficiency suppresses cardiac fibrosis and left ventricular dysfunction in male mice., Nature Communications, Vol.15, No.1, 2472, 2024. (Keyword) Animals / male / knockout mice / Fibroblasts / Fibrosis / heart / Protein-Arginine N-Methyltransferases / Transforming Growth Factor beta / Ventricular Dysfunction, Left (Link to Publication Site) ● Publication site (DOI): 10.1038/s41467-024-46711-z (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38503742 ● Search Scopus @ Elsevier (PMID): 38503742 ● Search Scopus @ Elsevier (DOI): 10.1038/s41467-024-46711-z (DOI: 10.1038/s41467-024-46711-z, PubMed: 38503742)
3.	Yoichi Sunagawa, Ryosuke Tsukabe, Yudai Irokawa, Masafumi Funamoto, Yuto Suzuki, Miho Yamada, Satoshi Shimizu, Yasufumi Katanasaka, Toshihide Hamabe-Horiike, Yuto Kawase, Ryuya Naruta, Kana Shimizu, Kiyoshi Mori, Ryota Hosomi, Maki Komiyama, Koji Hasegawa and Tatsuya Morimoto : Anserine, a Histidine-Containing Dipeptide, Suppresses Pressure Overload-Induced Systolic Dysfunction by Inhibiting Histone Acetyltransferase Activity of p300 in Mice., International Journal of Molecular Sciences, Vol.25, No.4, 2344, 2024. (Keyword) Animals / Humans / male / Mice / Acetylation / Anserine / Cardiomegaly / Cardiomyopathies / Enzyme Inhibitors / heart failure / Histones / Mice, Inbred C57BL / Myocytes, Cardiac / Phenylephrine / p300-CBP Transcription Factors (Tokushima University Institutional Repository) ● Metadata: 119246 (Link to Publication Site) ● Publication site (DOI): 10.3390/ijms25042344 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38397020 ● Search Scopus @ Elsevier (PMID): 38397020 ● Search Scopus @ Elsevier (DOI): 10.3390/ijms25042344 (Tokushima University Institutional Repository: 119246, DOI: 10.3390/ijms25042344, PubMed: 38397020)
4.	Xi Chen, Asadur Rahman, Steeve Akumwami, Asahiro Morishita, Kento Kitada, Yasumasa Ikeda, Masafumi Funamoto and Akira Nishiyama : Effects of D-allose on ATP production and cell viability in neonatal rat cardiomyocytes., Journal of Pharmacological Sciences, Vol.154, No.4, 274-278, 2024. (Summary) 2-Deoxy-d-glucose (2DG) induces anticancer effects through glycolytic inhibition but it may raise the risk of arrhythmia. The rare monosaccharide d-allose also has anticancer properties, but its cardiac effects are unknown. We examined the effects of d-allose on adenosine triphosphate (ATP) production in neonatal rat cardiomyocytes. We showed that 25 mM d-allose selectively reduced glycolytic ATP, but had minimal impact on mitochondrial ATP, while 1 mM 2DG strongly inhibited both. Furthermore, d-allose had less impact on cell viability and was less cytotoxic than 2DG; neither compound caused apoptosis. Thus, d-allose selectively diminished glycolytic ATP production with no apparent effects on cardiomyocytes. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jphs.2024.02.009 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38485345 ● Search Scopus @ Elsevier (PMID): 38485345 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jphs.2024.02.009 (DOI: 10.1016/j.jphs.2024.02.009, PubMed: 38485345)
5.	Honoka Tsunematsu, Masaki Imanishi, Yuka Uemura, Yoshiya Higaki, Miyu Morisaki, Akari Katsura, Licht Miyamoto, Masafumi Funamoto, Mayuko Ichimura-Shimizu, Yuya Horinouchi, Yasumasa Ikeda, Koichi Tsuneyama and Koichiro Tsuchiya : Indigo Leaves-Induced Pulmonary Arterial Remodeling without Right Ventricular Hypertrophy in Rats., Biological & Pharmaceutical Bulletin, Vol.47, No.7, 1350-1359, 2024. (Summary) Indigo naturalis (IN), derived from the leaves of the indigo plant, is a traditional Chinese medicine that has historically been used for its anti-inflammatory properties in the treatment of various diseases, including ulcerative colitis (UC). However, long-term use of IN in UC patients is incontrovertibly associated with the onset of pulmonary arterial hypertension (PAH). To investigate the mechanisms by which IN induces PAH, we focused on the raw material of IN, indigo leaves (IL). Only the condition of long-term chronic (6 months) and high-dose (containing 5% IL in the control diet) administration of IL induced medial thickening in the pulmonary arteries without right ventricular hypertrophy in our rat model. IL administration for a month did not induce pulmonary arterial remodeling but increased endothelin-1 (ET-1) expression levels within endothelial cell (EC) layers in the lungs. Gene Expression Omnibus analysis showed that ET-1 is a key regulator of PAH and that the IL component indican and its metabolite IS induced ET-1 mRNA expression via reactive oxygen species-dependent mechanism. We identified the roles of indican and IS in ET-1 expression in ECs, which were linked to pulmonary arterial remodeling in an animal model. (Keyword) Animals / Plant Leaves / Pulmonary Artery / Male / Endothelin-1 / Vascular Remodeling / Hypertrophy, Right Ventricular / Rats, Sprague-Dawley / Hypertension, Pulmonary / Rats / Endothelial Cells / Lung (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b24-00289 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39085074 ● CiNii @ National Institute of Informatics (CRID): 1390863937794660096 ● Summary page in Scopus @ Elsevier: 2-s2.0-85199865455 (DOI: 10.1248/bpb.b24-00289, PubMed: 39085074, CiNii: 1390863937794660096, Elsevier: Scopus)
6.	Swati Mittal, Maki Komiyama, Yuka Ozaki, Hajime Yamakage, Noriko Satoh-Asahara, Hiromichi Wada, Akihiro Yasoda, Masafumi Funamoto, Yasufumi Katanasaka, Yoichi Sunagawa, Tatsuya Morimoto, Masaharu Akao, Mitsuru Abe, Yuko Takahashi, Takeo Nakayama and Koji Hasegawa : Impact of smoking initiation age on nicotine dependency and cardiovascular risk factors: a retrospective cohort study in Japan., European Heart Journal Open, Vol.4, No.1, 2023. (Link to Publication Site) ● Publication site (DOI): 10.1093/ehjopen/oead135 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38250139 ● Search Scopus @ Elsevier (PMID): 38250139 ● Search Scopus @ Elsevier (DOI): 10.1093/ehjopen/oead135 (DOI: 10.1093/ehjopen/oead135, PubMed: 38250139)
7.	Masaki Imanishi, Takahisa Inoue, Keijo Fukushima, Ryosuke Yamashita, Ryo Nakayama, Masataka Nojima, Kosuke Kondo, Yoshiki Gomi, Honoka Tsunematsu, Kohei Goto, Licht Miyamoto, Masafumi Funamoto, Masaya Denda, Keisuke Ishizawa, Akira Otaka, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya : CA9 and PRELID2; hypoxia-responsive potential therapeutic targets for pancreatic ductal adenocarcinoma as per bioinformatics analyses., Journal of Pharmacological Sciences, Vol.153, No.4, 232-242, 2023. (Summary) A strong hypoxic environment has been observed in pancreatic ductal adenocarcinoma (PDAC) cells, which contributes to drug resistance, tumor progression, and metastasis. Therefore, we performed bioinformatics analyses to investigate potential targets for the treatment of PDAC. To identify potential genes as effective PDAC treatment targets, we selected all genes whose expression level was related to worse overall survival (OS) in The Cancer Genome Atlas (TCGA) database and selected only the genes that matched with the genes upregulated due to hypoxia in pancreatic cancer cells in the dataset obtained from the Gene Expression Omnibus (GEO) database. Although the extracted 107 hypoxia-responsive genes included the genes that were slightly enriched in angiogenic factors, TCGA data analysis revealed that the expression level of endothelial cell (EC) markers did not affect OS. Finally, we selected CA9 and PRELID2 as potential targets for PDAC treatment and elucidated that a CA9 inhibitor, U-104, suppressed pancreatic cancer cell growth more effectively than 5-fluorouracil (5-FU) and PRELID2 siRNA treatment suppressed the cell growth stronger than CA9 siRNA treatment. Thus, we elucidated that specific inhibition of PRELID2 as well as CA9, extracted via exhaustive bioinformatic analyses of clinical datasets, could be a more effective strategy for PDAC treatment. (Keyword) Humans / Carbonic Anhydrase IX / Antigens, Neoplasm / Carcinoma, Pancreatic Ductal / Pancreatic Neoplasms / Hypoxia / RNA, Small Interfering / Computational Biology / Pancreatic Neoplasms (Tokushima University Institutional Repository) ● Metadata: 119176 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jphs.2023.10.003 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37973221 ● CiNii @ National Institute of Informatics (CRID): 1872553967456110848 ● Search Scopus @ Elsevier (PMID): 37973221 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jphs.2023.10.003 (Tokushima University Institutional Repository: 119176, DOI: 10.1016/j.jphs.2023.10.003, PubMed: 37973221, CiNii: 1872553967456110848)
8.	Aoi Suenaga, Yasuyuki Seto, Masafumi Funamoto, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : TJ-17 (Goreisan) mitigates renal fibrosis in a mouse model of folic acid-induced chronic kidney disease., Journal of Pharmacological Sciences, Vol.153, No.1, 31-37, 2023. (Summary) TJ-17 may have a novel preventive effect against inflammation, oxidative stress, and fibrosis, contributing to innovation in the treatment of CKD. (Tokushima University Institutional Repository) ● Metadata: 118452 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jphs.2023.07.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37524452 ● Search Scopus @ Elsevier (PMID): 37524452 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jphs.2023.07.001 (Tokushima University Institutional Repository: 118452, DOI: 10.1016/j.jphs.2023.07.001, PubMed: 37524452)
9.	Yuto Kawase, Yoichi Sunagawa, Kana Shimizu, Masafumi Funamoto, Toshihide Hamabe-Horiike, Yasufumi Katanasaka, Satoshi Shimizu, Philip Hawke, Kiyoshi Mori, Maki Komiyama, Koji Hasegawa and Tatsuya Morimoto : 6-Shogaol, an Active Component of Ginger, Inhibits p300 Histone Acetyltransferase Activity and Attenuates the Development of Pressure-Overload-Induced Heart Failure., Nutrients, Vol.15, No.9, 2232, 2023. (Keyword) Animals / knockout mice / Rats / Zingiber officinale / Acetylation / Histones / heart failure / Aortic Valve Stenosis / Anti-Arrhythmia Agents / Cardiotonic Agents / Diuretics / Glycosides (Link to Publication Site) ● Publication site (DOI): 10.3390/nu15092232 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37432400 ● Search Scopus @ Elsevier (PMID): 37432400 ● Search Scopus @ Elsevier (DOI): 10.3390/nu15092232 (DOI: 10.3390/nu15092232, PubMed: 37432400)
10.	Yoichi Sunagawa, Shogo Kawaguchi, Yusuke Miyazaki, Yasufumi Katanasaka, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Toshihide Hamabe-Horiike, Yuto Kawase, Maki Komiyama, Kiyoshi Mori, Akira Murakami, Koji Hasegawa and Tatsuya Morimoto : Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart failure by activating PPARα in rats., Phytomedicine, Vol.107, 154457, 2022. (Summary) Auraptene has beneficial effects on MI-induced cardiac hypertrophy and left ventricular systolic dysfunction in rats, at least partly due to PPARα activation. Further clinical studies are required to evaluate the efficacy of auraptene in patients with HF. (Keyword) Animals / Rats / Atrial Natriuretic Factor / Biological Products / Cardiomegaly / Citrus / Coumarins / Endothelin-1 / Fibrosis / heart failure / Myocardial Infarction / Peroxisome Proliferators / Phenylephrine / PPAR alpha / Rats, Sprague-Dawley / RNA, Messenger (Link to Publication Site) ● Publication site (DOI): 10.1016/j.phymed.2022.154457 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36223697 ● Search Scopus @ Elsevier (PMID): 36223697 ● Search Scopus @ Elsevier (DOI): 10.1016/j.phymed.2022.154457 (DOI: 10.1016/j.phymed.2022.154457, PubMed: 36223697)
11.	Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Toru Kato, Junichi Funada, Yoichi Ajiro, Maki Komiyama, Masaharu Akao, Akihiro Yasoda, Hajime Yamakage, Noriko Satoh-Asahara, Hiromichi Wada, Yasumasa Ikeda, Tatsuya Morimoto and Koji Hasegawa : Effects of high-absorption curcumin for the prevention of hypertensive heart disease: a double-blind, placebo-controlled, randomized clinical study., European Heart Journal Open, Vol.107, 154457, 2022. (Summary) ' ratio, rather it significantly inhibited the increase in plasma BNP levels in patients with initial signs of hypertensive heart disease. (Tokushima University Institutional Repository) ● Metadata: 118447 (Link to Publication Site) ● Publication site (DOI): 10.1093/ehjopen/oeac057 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36172003 ● Search Scopus @ Elsevier (PMID): 36172003 ● Search Scopus @ Elsevier (DOI): 10.1093/ehjopen/oeac057 (Tokushima University Institutional Repository: 118447, DOI: 10.1093/ehjopen/oeac057, PubMed: 36172003)
12.	Masafumi Funamoto, Yoichi Sunagawa, Mai Gempei, Kana Shimizu, Yasufumi Katanasaka, Satoshi Shimizu, Toshihide Hamabe-Horiike, Giovanni Appendino, Alberto Minassi, Andreas Koeberle, Maki Komiyama, Kiyoshi Mori, Koji Hasegawa and Tatsuya Morimoto : Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1 Complex., Pharmaceutics, Vol.14, No.6, 1269, 2022. (Summary) The intrinsic histone acetyltransferase (HAT), p300, has an important role in the development and progression of heart failure. Curcumin (CUR), a natural p300-specific HAT inhibitor, suppresses hypertrophic responses and prevents deterioration of left-ventricular systolic function in heart-failure models. However, few structure-activity relationship studies on cardiomyocyte hypertrophy using CUR have been conducted. To evaluate if prenylated pyrazolo curcumin (PPC) and curcumin pyrazole (PyrC) can suppress cardiomyocyte hypertrophy, cultured cardiomyocytes were treated with CUR, PPC, or PyrC and then stimulated with phenylephrine (PE). PE-induced cardiomyocyte hypertrophy was inhibited by PyrC but not PPC at a lower concentration than CUR. Western blotting showed that PyrC suppressed PE-induced histone acetylation. However, an in vitro HAT assay showed that PyrC did not directly inhibit p300-HAT activity. As Cdk9 phosphorylates both RNA polymerase II and p300 and increases p300-HAT activity, the effects of CUR and PyrC on the kinase activity of Cdk9 were examined. Phosphorylation of p300 by Cdk9 was suppressed by PyrC. Immunoprecipitation-WB showed that PyrC inhibits Cdk9 binding to CyclinT1 in cultured cardiomyocytes. PyrC may prevent cardiomyocyte hypertrophic responses by indirectly suppressing both p300-HAT activity and RNA polymerase II transcription elongation activity via inhibition of Cdk9 kinase activity. (Tokushima University Institutional Repository) ● Metadata: 118446 (Link to Publication Site) ● Publication site (DOI): 10.3390/pharmaceutics14061269 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35745840 ● Search Scopus @ Elsevier (PMID): 35745840 ● Search Scopus @ Elsevier (DOI): 10.3390/pharmaceutics14061269 (Tokushima University Institutional Repository: 118446, DOI: 10.3390/pharmaceutics14061269, PubMed: 35745840)
13.	Yasumasa Ikeda, Masafumi Funamoto, Seiji Kishi, Masaki Imanishi, Ken-ichi Aihara, Yoshiki Kashiwada and Koichiro Tsuchiya : The novel preventive effect of a Japanese ethical Kampo extract formulation TJ-90 (Seihaito) against cisplatin-induced nephrotoxicity, Phytomedicine, Vol.103, No.8, 154213, 2022. (Tokushima University Institutional Repository) ● Metadata: 117134 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.phymed.2022.154213 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.phymed.2022.154213 (Tokushima University Institutional Repository: 117134, DOI: 10.1016/j.phymed.2022.154213)
14.	Yoichi Sunagawa, Ayumi Katayama, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Nurmila Sari, Yasufumi Katanasaka, Yusuke Miyazaki, Ryota Hosomi, Koji Hasegawa and Tatsuya Morimoto : The polyunsaturated fatty acids, EPA and DHA, ameliorate myocardial infarction-induced heart failure by inhibiting p300-HAT activity in rats., The Journal of Nutritional Biochemistry, Vol.106, 109031, 2022. (Summary) While the cardioprotective functions of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and omega-3 unsaturated fatty acids have been previously demonstrated, little is known about their effects on cardiomyocyte hypertrophy. In this study, we compared the effects of EPA and DHA on hypertrophic responses in cardiomyocytes and development of heart failure in rats with myocardial infarction (MI). Both EPA and DHA significantly suppressed phenylephrine- and p300-induced cardiomyocyte hypertrophy, transcription of hypertrophy response genes, and acetylation of histone H3K9 in cardiomyocytes. EPA and DHA directly inhibited p300-histone acetyltransferase activity (IC50: 37.8 and 30.6 μM, respectively). Further, EPA- and DHA-induced allosteric inhibition of histones and competitive inhibition of acetyl-CoA, and significantly prevented p300-induced hypertrophic responses. Rats with moderate MI (left ventricular fractional shortening [FS] <40%) were randomly assigned to three groups, namely, vehicle (saline), EPA (1 g/kg), and DHA (1 g/kg). One week after the operation, rats were orally administrated with test agents for 6 weeks. Echocardiographic analysis demonstrated that both EPA and DHA treatments preserved FS and prevented MI-induced left ventricular remodeling. Furthermore, EPA and DHA significantly suppressed the MI-induced increase in myocardial cell diameter, perivascular fibrosis, mRNA levels of hypertrophic markers, fibrosis, and acetylation of histone H3K9. The effects on hypertrophic responses and the development of heart failure were not different between EPA and DHA groups. Both EPA and DHA suppressed hypertrophic responses and the development of heart failure to the same extent through the inhibition of p300-HAT activity. (Keyword) Animals / Docosahexaenoic Acids / Eicosapentaenoic Acid / Fibrosis / heart failure / Histones / Hypertrophy / Myocardial Infarction / Rats (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jnutbio.2022.109031 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35504444 ● Search Scopus @ Elsevier (PMID): 35504444 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jnutbio.2022.109031 (DOI: 10.1016/j.jnutbio.2022.109031, PubMed: 35504444)
15.	Yasufumi Katanasaka, Ayumi Saito, Yoichi Sunagawa, Nurmila Sari, Masafumi Funamoto, Satoshi Shimizu, Kana Shimizu, Takehide Akimoto, Chikara Ueki, Mitsuru Kitano, Koji Hasegawa, Genichi Sakaguchi and Tatsuya Morimoto : ANGPTL4 Expression Is Increased in Epicardial Adipose Tissue of Patients with Coronary Artery Disease., Journal of Clinical Medicine, Vol.11, No.9, 2449, 2022. (Summary) Epicardial adipose tissue (EAT) is known to affect atherosclerosis and coronary artery disease (CAD) pathogenesis, persistently releasing pro-inflammatory adipokines that affect the myocardium and coronary arteries. Angiopoietin-like 4 (ANGPTL4) is a protein secreted from adipose tissue and plays a critical role in the progression of atherosclerosis. Here, the expression of ANGPTL4 in EAT was investigated in CAD subjects. Thirty-four consecutive patients (13 patients with significant CAD; 21 patients without CAD) undergoing elective open-heart surgery were recruited. EAT and pericardial fluid were obtained at the time of surgery. mRNA expression and ANGPTL4 and IL-1β levels were evaluated by qRT-PCR and ELISA. The expression of ANGPTL4 (p = 0.0180) and IL-1β (p < 0.0001) in EAT significantly increased in the CAD group compared to that in the non-CAD group and positively correlated (p = 0.004). Multiple regression analysis indicated that CAD is a contributing factor for ANGPTL4 expression in EAT. IL-1β level in the pericardial fluid was significantly increased in patients with CAD (p = 0.020). Moreover, the expression of ANGPTL4 (p = 0.004) and IL-1β (p < 0.001) in EAT was significantly increased in non-obese patients with CAD. In summary, ANGPTL4 expression in EAT was increased in CAD patients. (Tokushima University Institutional Repository) ● Metadata: 118445 (Link to Publication Site) ● Publication site (DOI): 10.3390/jcm11092449 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35566578 ● Search Scopus @ Elsevier (PMID): 35566578 ● Search Scopus @ Elsevier (DOI): 10.3390/jcm11092449 (Tokushima University Institutional Repository: 118445, DOI: 10.3390/jcm11092449, PubMed: 35566578)
16.	Takahiro Katagiri, Yoichi Sunagawa, Tatsuya Maekawa, Masafumi Funamoto, Satoshi Shimizu, Kana Shimizu, Yasufumi Katanasaka, Maki Komiyama, Philip Hawke, Hideo Hara, Kiyoshi Mori, Koji Hasegawa and Tatsuya Morimoto : Okamura Extract Suppresses Myocardial Infarction-Induced Left Ventricular Systolic Dysfunction by Inhibiting p300-HAT Activity., Nutrients, Vol.14, No.3, 580, 2022. (Summary) Ecklonia stolonifera Okamura extract (ESE) has been reported to have various bioactive effects, but its effects on cardiovascular disease have not yet been investigated. First, primary neonatal rat cultured cardiomyocytes were treated with ESE and stimulated with phenylephrine (PE) for 48 h. ESE (1000 µg/mL) significantly suppressed PE-induced cardiomyocyte hypertrophy, hypertrophy-related gene transcription, and the acetylation of histone H3K9. An in vitro p300-HAT assay indicated that ESE directly inhibited p300-HAT activity. Next, one week after myocardial infarction (MI) surgery, rats (left ventricular fractional shortening (LVFS) < 40%) were randomly assigned to three groups: vehicle (saline, n = 9), ESE (0.3 g/kg, n = 10), or ESE (1 g/kg, n = 10). Daily oral administration was carried out for 8 weeks. After treatment, LVFS was significantly higher in the ESE (1 g/kg) group than in the vehicle group. The ESE treatments also significantly suppressed MI-induced increases in myocardial cell diameter, perivascular fibrosis, hypertrophy- and fibrosis-related gene transcription, and the acetylation of histone H3K9. These results suggest that ESE suppressed both hypertrophic responses in cardiomyocytes and the development of heart failure in rats by inhibiting p300-HAT activity. Thus, this dietary extract is a potential novel therapeutic strategy for heart failure in humans. (Keyword) Animals / heart failure / Myocardial Infarction / Myocytes, Cardiac / Phaeophyta / Plant Extracts / Rats (Tokushima University Institutional Repository) ● Metadata: 118443 (Link to Publication Site) ● Publication site (DOI): 10.3390/nu14030580 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35276939 ● Search Scopus @ Elsevier (PMID): 35276939 ● Search Scopus @ Elsevier (DOI): 10.3390/nu14030580 (Tokushima University Institutional Repository: 118443, DOI: 10.3390/nu14030580, PubMed: 35276939)
17.	Masaya Ono, Yoichi Sunagawa, Saho Mochizuki, Takahiro Katagiri, Hidemichi Takai, Sonoka Iwashimizu, Kyoko Inai, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Yasufumi Katanasaka, Maki Komiyama, Philip Hawke, Hideo Hara, Yoshiki Arakawa, Kiyoshi Mori, Akira Asai, Koji Hasegawa and Tatsuya Morimoto : Extract Ameliorates Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis., Cancers, Vol.14, No.3, 683, 2022. (Link to Publication Site) ● Publication site (DOI): 10.3390/cancers14030683 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35158951 ● Search Scopus @ Elsevier (PMID): 35158951 ● Search Scopus @ Elsevier (DOI): 10.3390/cancers14030683 (DOI: 10.3390/cancers14030683, PubMed: 35158951)
18.	Satoshi Shimizu, Yoichi Sunagawa, Naruto Hajika, Natsumi Yorimitsu, Yasufumi Katanasaka, Masafumi Funamoto, Yusuke Miyazaki, Nurmila Sari, Kana Shimizu, Koji Hasegawa and Tatsuya Morimoto : Multimerization of the GATA4 transcription factor regulates transcriptional activity and cardiomyocyte hypertrophic response., International Journal of Biological Sciences, Vol.18, No.3, 1079-1095, 2022. (Link to Publication Site) ● Publication site (DOI): 10.7150/ijbs.65664 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35173540 ● CiNii @ National Institute of Informatics (CRID): 1360576118771335168 ● Summary page in Scopus @ Elsevier: 2-s2.0-85124777954 (DOI: 10.7150/ijbs.65664, PubMed: 35173540, CiNii: 1360576118771335168, Elsevier: Scopus)
19.	Kana Shimizu, Yoichi Sunagawa, Masafumi Funamoto, Hiroki Honda, Yasufumi Katanasaka, Noriyuki Murai, Yuto Kawase, Yuta Hirako, Takahiro Katagiri, Harumi Yabe, Satoshi Shimizu, Nurmila Sari, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2-GATA4 Signaling Pathway, Pharmaceuticals, Vol.14, No.12, 1268, 2021. (Summary) Drug repositioning has recently emerged as a strategy for developing new treatments at low cost. In this study, we used a library of approved drugs to screen for compounds that suppress cardiomyocyte hypertrophy. We identified the antiplatelet drug sarpogrelate, a selective serotonin-2A (5-HT) receptor antagonist, and investigated the drug's anti-hypertrophic effect in cultured cardiomyocytes and its effect on heart failure in vivo. Primary cultured cardiomyocytes pretreated with sarpogrelate were stimulated with angiotensin II, endothelin-1, or phenylephrine. Immunofluorescence staining showed that sarpogrelate suppressed the cardiomyocyte hypertrophy induced by each of the stimuli. Western blotting analysis revealed that 5-HT receptor level was not changed by phenylephrine, and that sarpogrelate suppressed phenylephrine-induced phosphorylation of ERK1/2 and GATA4. C57BL/6J male mice were subjected to transverse aortic constriction (TAC) surgery followed by daily oral administration of sarpogrelate for 8 weeks. Echocardiography showed that 5 mg/kg of sarpogrelate suppressed TAC-induced cardiac hypertrophy and systolic dysfunction. Western blotting revealed that sarpogrelate suppressed TAC-induced phosphorylation of ERK1/2 and GATA4. These results indicate that sarpogrelate suppresses the development of heart failure and that it does so at least in part by inhibiting the ERK1/2-GATA4 signaling pathway. (Link to Publication Site) ● Publication site (DOI): 10.3390/ph14121268 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34959669 ● Summary page in Scopus @ Elsevier: 2-s2.0-85121331216 (DOI: 10.3390/ph14121268, PubMed: 34959669, Elsevier: Scopus)
20.	Yasufumi Katanasaka, Naoki Yoshida, Hirotaka Naitou, Ryuya Naruta, Yusuke Miyazaki, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Numila Sari, Hajime Yamakage, Noriko Satoh-Asahara, Koji Hasegawa and Tatsuya Morimoto : Effect of Theaflavin on Oral Bacteria in Japanese Subjects: A Randomized, Placebo-Controlled, Double-Blind Study., Journal of Medicinal Food, Vol.24, No.11, 1186-1190, 2021. (Keyword) Aggregatibacter actinomycetemcomitans / Biflavonoids / catechin / Double-Blind Method / Fusobacterium nucleatum / Humans / Japan / Pilot Projects / Porphyromonas gingivalis (Link to Publication Site) ● Publication site (DOI): 10.1089/jmf.2021.K.0050 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34698557 ● Search Scopus @ Elsevier (PMID): 34698557 ● Search Scopus @ Elsevier (DOI): 10.1089/jmf.2021.K.0050 (DOI: 10.1089/jmf.2021.K.0050, PubMed: 34698557)
21.	Nurmila Sari, Yasufumi Katanasaka, Yuga Sugiyama, Yoichi Sunagawa, Yusuke Miyazaki, Masafumi Funamoto, Satoshi Shimizu, Kana Shimizu, Akira Murakami, Kiyoshi Mori, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Zerumbone prevents pressure overload-induced left ventricular systolic dysfunction by inhibiting cardiac hypertrophy and fibrosis., Phytomedicine, Vol.92, 153744, 2021. (Keyword) Animals / Cardiomegaly / Fibrosis / Male / Mice / Mice, Inbred C57BL / myocardium / Myocytes, Cardiac / Rats / Sesquiterpenes / Ventricular Remodeling (Link to Publication Site) ● Publication site (DOI): 10.1016/j.phymed.2021.153744 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34563985 ● Search Scopus @ Elsevier (PMID): 34563985 ● Search Scopus @ Elsevier (DOI): 10.1016/j.phymed.2021.153744 (DOI: 10.1016/j.phymed.2021.153744, PubMed: 34563985)
22.	Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Nurmila Sari, Yasufumi Katanasaka, Yusuke Miyazaki, Hideaki Kakeya, Koji Hasegawa and Tatsuya Morimoto : Curcumin, an Inhibitor of p300-HAT Activity, Suppresses the Development of Hypertension-Induced Left Ventricular Hypertrophy with Preserved Ejection Fraction in Dahl Rats., Nutrients, Vol.13, No.8, 2608, 2021. (Keyword) Acetylation / Animals / blood pressure / Curcumin / Fibrosis / heart failure / hypertension / Hypertrophy, Left Ventricular / Male / Myocytes, Cardiac / Rats / Rats, Inbred Dahl / Sodium Chloride, Dietary / Stroke Volume (Link to Publication Site) ● Publication site (DOI): 10.3390/nu13082608 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34444769 ● Search Scopus @ Elsevier (PMID): 34444769 ● Search Scopus @ Elsevier (DOI): 10.3390/nu13082608 (DOI: 10.3390/nu13082608, PubMed: 34444769)
23.	Yoichi Sunagawa, Kiyotaka Shimizu, Ayumi Katayama, Masafumi Funamoto, Kana Shimizu, Sari Nurmila, Satoshi Shimizu, Yusuke Miyazaki, Yasufumi Katanasaka, Koji Hasegawa and Tatsuya Morimoto : Metformin suppresses phenylephrine-induced hypertrophic responses by inhibiting p300-HAT activity in cardiomyocytes., Journal of Pharmacological Sciences, Vol.147, No.2, 169-175, 2021. (Keyword) Acetylation / Adrenergic alpha-1 Receptor Agonists / Animals / Cardiomegaly / Cells, Cultured / E1A-Associated p300 Protein / heart failure / Histone Acetyltransferases / Metformin / Myocytes, Cardiac / Phenylephrine / Rats, Sprague-Dawley (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jphs.2021.07.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34384564 ● Search Scopus @ Elsevier (PMID): 34384564 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jphs.2021.07.001 (DOI: 10.1016/j.jphs.2021.07.001, PubMed: 34384564)
24.	Maki Komiyama, Yuka Ozaki, Yusuke Miyazaki, Yasufumi Katanasaka, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Hajime Yamakage, Noriko Sato-Asahara, Akihiro Yasoda, Hiromichi Wada, Tatsuya Morimoto and Koji Hasegawa : Neutrophil/lymphocyte ratio is correlated with levels of inflammatory markers and is significantly reduced by smoking cessation., The Journal of International Medical Research, Vol.49, No.6, 3000605211019223, 2021. (Keyword) Biomarkers / Female / Humans / Lymphocytes / Male / Neutrophils / smoking / Smoking Cessation (Link to Publication Site) ● Publication site (DOI): 10.1177/03000605211019223 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34187206 ● Search Scopus @ Elsevier (PMID): 34187206 ● Search Scopus @ Elsevier (DOI): 10.1177/03000605211019223 (DOI: 10.1177/03000605211019223, PubMed: 34187206)
25.	Swati Mittal, Maki Komiyama, Yuka Ozaki, Hajime Yamakage, Noriko Satoh-Asahara, Akihiro Yasoda, Hiromichi Wada, Masafumi Funamoto, Kana Shimizu, Yusuke Miyazaki, Yasufumi Katanasaka, Yoichi Sunagawa, Tatsuya Morimoto, Yuko Takahashi, Takeo Nakayama and Koji Hasegawa : Gingival bleeding and pocket depth among smokers and the related changes after short-term smoking cessation, Acta Odontologica Scandinavica, Vol.80, No.4, 258-263, 2021. (Summary) Smoking is associated with the deteriorating health of the gingiva and periodontium. The long-term beneficial effects of smoking cessation on oral health are well known. However, the effects of short-term smoking cessation on gingival bleeding and periodontal pocket depth are unknown. The purpose of the present study was to determine the effects of short-term smoking cessation on gingival bleeding and periodontal pocket depth. Dentate smokers with a mean age of 56.9 ± 14.4 years at an outpatient smoking cessation clinic participated in this study. A professional dentist checked the periodontal pocket depth and gingival bleeding. Patients visited the smoking cessation clinic on their first visit and 2, 4, 8, and 12 weeks (three months). The gingival assessment was re-performed in those who succeeded in smoking cessation 3 months after the baseline. The baseline data of 83 patients showed that an increase in pocket depth was associated with increasing age and the amount of smoking. A significant increase in gingival bleeding ( = .031) and increase in pocket depth ( = .046) were observed 3 months after the baseline in patients who successfully quit smoking ( = 14). Short-term smoking cessation increased periodontal pocket depth and gingival bleeding. These findings may reflect healing processes that occur in the healthy gingiva. Study findings will be useful to advise patients during smoking cessation programs. Dentists can inform patients that an initial increase in gingival bleeding and pocket depth could be associated with smoking cessation. Such advice will prevent patients from any apprehension that may cause them to recommence smoking. (Tokushima University Institutional Repository) ● Metadata: 118442 (Link to Publication Site) ● Publication site (DOI): 10.1080/00016357.2021.1995040 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34893003 ● Summary page in Scopus @ Elsevier: 2-s2.0-85121388107 (Tokushima University Institutional Repository: 118442, DOI: 10.1080/00016357.2021.1995040, PubMed: 34893003, Elsevier: Scopus)
26.	Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Kana Shimizu, Yusuke Miyazaki, Nurmila Sari, Satoshi Shimizu, Kiyoshi Mori, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Histone Acetylation Domains Are Differentially Induced during Development of Heart Failure in Dahl Salt-Sensitive Rats, International Journal of Molecular Sciences, Vol.22, No.4, 1771, 2021. (Summary) Histone acetylation by epigenetic regulators has been shown to activate the transcription of hypertrophic response genes, which subsequently leads to the development and progression of heart failure. However, nothing is known about the acetylation of the histone tail and globular domains in left ventricular hypertrophy or in heart failure. The acetylation of H3K9 on the promoter of the hypertrophic response gene was significantly increased in the left ventricular hypertrophy stage, whereas the acetylation of H3K122 did not increase in the left ventricular hypertrophy stage but did significantly increase in the heart failure stage. Interestingly, the interaction between the chromatin remodeling factor BRG1 and p300 was significantly increased in the heart failure stage, but not in the left ventricular hypertrophy stage. This study demonstrates that stage-specific acetylation of the histone tail and globular domains occurs during the development and progression of heart failure, providing novel insights into the epigenetic regulatory mechanism governing transcriptional activity in these processes. (Keyword) Acetylation / Animals / Cell Culture Techniques / DNA Helicases / E1A-Associated p300 Protein / Heart Failure / Histones / Hypertrophy, Left Ventricular / Male / Mice, Inbred C57BL / Myocytes, Cardiac / Rats, Inbred Dahl / Rats, Sprague-Dawley / Transcription Factors (Link to Publication Site) ● Publication site (DOI): 10.3390/ijms22041771 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33578969 ● Summary page in Scopus @ Elsevier: 2-s2.0-85100583278 (DOI: 10.3390/ijms22041771, PubMed: 33578969, Elsevier: Scopus)
27.	Yasufumi Katanasaka, Sae Hirano, Yoichi Sunagawa, Yusuke Miyazaki, Hikaru Sato, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Nurmila Sari, Koji Hasegawa and Tatsuya Morimoto : Clinically Administered Doses of Pitavastatin and Rosuvastatin., International Heart Journal, Vol.62, No.6, 1379-1386, 2021. (Summary) Clinical studies have indicated that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, can potentially inhibit chronic heart failure. In the Stat-LVDF study, a difference was noted in terms of the effect of lipophilic pitavastatin (PTV) and hydrophilic rosuvastatin (RSV) on plasma BNP, suggesting that statin lipophilicity and pharmacokinetics change the pleiotropic effect on heart failure in humans. Therefore, we assessed the beneficial effects of PTV on hypertrophy in cardiac myocytes compared with RSV at clinically used doses. Cultured cardiomyocytes were stimulated with 30 μM phenylephrine (PE) in the presence of PTV (250 nM) or RSV (50 nM). These doses were calculated based on the maximum blood concentration of statins used in clinical situations in Japan. The results showed that PTV, but not RSV, significantly inhibits the PE-induced increase in cell size and leucine incorporation without causing cell toxicity. In addition, PTV significantly suppressed PE-induced mRNA expression of hypertrophic response genes. PE-induced ERK phosphorylation was inhibited by PTV, but not by RSV. Furthermore, PTV significantly suppressed the angiotensin-II-induced proline incorporation in primary cultured cardiac fibroblasts. In conclusion, a clinical dose of PTV was noted to directly inhibit cardiomyocyte hypertrophy and cardiac fibrosis, suggesting that lipophilic PTV can be a potential drug candidate against chronic heart failure. (Keyword) Actins / Animals / Atrial Natriuretic Factor / Cells, Cultured / Extracellular Signal-Regulated MAP Kinases / gene expression / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hypertrophy / Leucine / Myocytes, Cardiac / Natriuretic Peptide, Brain / phosphorylation / Quinolines / RNA, Messenger / Rats, Sprague-Dawley / Rosuvastatin Calcium (Link to Publication Site) ● Publication site (DOI): 10.1536/ihj.21-231 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34853228 ● Search Scopus @ Elsevier (PMID): 34853228 ● Search Scopus @ Elsevier (DOI): 10.1536/ihj.21-231 (DOI: 10.1536/ihj.21-231, PubMed: 34853228)
28.	Nurmila Sari, Yasufumi Katanasaka, Yuga Sugiyama, Yusuke Miyazaki, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Koji Hasegawa and Tatsuya Morimoto : Alpha Mangostin Derived from Garcinia magostana Linn Ameliorates Cardiomyocyte Hypertrophy and Fibroblast Phenotypes in Vitro., Biological & Pharmaceutical Bulletin, Vol.44, No.10, 1465-1472, 2021. (Summary) Cardiac hypertrophy and fibrosis are significant risk factors for chronic heart failure (HF). Since pharmacotherapy agents targeting these processes have not been established, we investigated the effect of alpha-magostin (α-man) on cardiomyocyte hypertrophy and fibrosis in vitro. Primary cultured cardiomyocytes and cardiac fibroblasts were prepared from neonatal rats. After α-man treatment, phenylephrine (PE) and transforming growth factor-beta (TGF-β) were added to the cardiomyocytes and cardiac fibroblasts to induce hypertrophic and fibrotic responses, respectively. Hypertrophic responses were assessed by measuring the cardiomyocyte surface area and hypertrophic gene expression levels. PE-induced phosphorylation of Akt, extracellular signal-regulated kinase (ERK)1/2, and p38 was examined by Western blotting. Fibrotic responses were assessed by measuring collagen synthesis, fibrotic gene expression levels, and myofibroblast differentiation. In addition, TGF-β-induced reactive oxygen species (ROS) production was investigated. In cultured cardiomyocytes, α-man significantly suppressed PE-induced increases in the cardiomyocyte surface area, and the mRNA levels (atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP)). Treatment with α-man significantly suppressed PE-induced Akt phosphorylation, but not ERK and p38 phosphorylation. In cultured cardiac fibroblasts, α-man significantly suppressed TGF-β-induced increases in L-proline incorporation, mRNA levels (POSTN and alpha-smooth muscle actin (α-SMA)), and myofibroblast differentiation. Additionally, it significantly inhibited TGF-β-induced reduced nicotinamide adenine dinucleotide phosphate oxidase4 (NOX4) expression and ROS production in cardiac fibroblasts. Treatment with α-man significantly ameliorates hypertrophy by inhibiting Akt phosphorylation in cardiomyocytes and fibrosis by inhibiting NOX4-generating ROS in fibroblasts. These findings suggest that α-man is a possible natural product for the prevention of cardiac hypertrophy and fibrosis. (Keyword) Animals / Cardiomegaly / Cells, Cultured / Disease Models, Animal / Fibroblasts / Fibrosis / Garcinia / heart / Humans / myocardium / Myocytes, Cardiac / NADPH Oxidase 4 / Primary Cell Culture / Rats / reactive oxygen species / Xanthones (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b21-00294 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34602555 ● Search Scopus @ Elsevier (PMID): 34602555 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b21-00294 (DOI: 10.1248/bpb.b21-00294, PubMed: 34602555)
29.	Nurmila Sari, Yasufumi Katanasaka, Hiroki Honda, Yusuke Miyazaki, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Cacao Bean Polyphenols Inhibit Cardiac Hypertrophy and Systolic Dysfunction in Pressure Overload-induced Heart Failure Model Mice., Planta Medica, Vol.86, No.17, 1304-1312, 2020. (Keyword) Animals / Cacao / Cardiomegaly / Disease Models, Animal / heart failure / Humans / Hypertrophy, Left Ventricular / Male / Mice / Mice, Inbred C57BL / Myocytes, Cardiac / Polyphenols / Rats (Link to Publication Site) ● Publication site (DOI): 10.1055/a-1191-7970 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32645737 ● Search Scopus @ Elsevier (PMID): 32645737 ● Search Scopus @ Elsevier (DOI): 10.1055/a-1191-7970 (DOI: 10.1055/a-1191-7970, PubMed: 32645737)
30.	Kana Shimizu, Yoichi Sunagawa, Masafumi Funamoto, Hiroki Wakabayashi, Mai Genpei, Yusuke Miyazaki, Yasufumi Katanasaka, Nurmila Sari, Satoshi Shimizu, Ayumi Katayama, Hiroyuki Shibata, Yoshiharu Iwabuchi, Hideaki Kakeya, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : The Synthetic Curcumin Analogue GO-Y030 Effectively Suppresses the Development of Pressure Overload-induced Heart Failure in Mice., Scientific Reports, Vol.10, No.1, 7172, 2020. (Keyword) Animals / Cardiomegaly / Curcumin / heart failure / Male / Mice / Myocytes, Cardiac / Rats / Rats, Sprague-Dawley (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-020-64207-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32346115 ● Search Scopus @ Elsevier (PMID): 32346115 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-020-64207-w (DOI: 10.1038/s41598-020-64207-w, PubMed: 32346115)
31.	Yasufumi Katanasaka, Yusuke Miyazaki, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Nurmila Sari, Yasuo Shimizu, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Kosen-cha, a Polymerized Catechin-Rich Green Tea, as a Potential Functional Beverage for the Reduction of Body Weight and Cardiovascular Risk Factors: A Pilot Study in Obese Patients., Biological & Pharmaceutical Bulletin, Vol.43, No.4, 675-681, 2020. (Keyword) adult / Body Weight / Cardiovascular Diseases / Catechin / Female / Functional Food / Humans / Male / Middle Aged / Obesity / Pilot Projects / Risk Factors / Tea (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b19-00921 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32238708 ● Search Scopus @ Elsevier (PMID): 32238708 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b19-00921 (DOI: 10.1248/bpb.b19-00921, PubMed: 32238708)
32.	Masafumi Funamoto, Kana Shimizu, Yoichi Sunagawa, Yasufumi Katanasaka, Yusuke Miyazaki, Maki Komiyama, Hajime Yamakage, Noriko Satoh-Asahara, Yuko Takahashi, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Serum Cystatin C, a Sensitive Marker of Renal Function and Cardiovascular Disease, Decreases After Smoking Cessation., Circulation Reports, Vol.1, No.12, 623-627, 2019. (Link to Publication Site) ● Publication site (DOI): 10.1253/circrep.CR-19-0052 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33693109 ● Search Scopus @ Elsevier (PMID): 33693109 ● Search Scopus @ Elsevier (DOI): 10.1253/circrep.CR-19-0052 (DOI: 10.1253/circrep.CR-19-0052, PubMed: 33693109)
33.	Masafumi Funamoto, Kana Shimizu, Yoichi Sunagawa, Yasufumi Katanasaka, Yusuke Miyazaki, Hideaki Kakeya, Hajime Yamakage, Noriko Satoh-Asahara, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus., Journal of Diabetes Research, Vol.2019, 8208237, 2019. (Keyword) Adiponectin / Administration, Oral / Adult / Aged / Aged, 80 and over / Antioxidants / Biomarkers / Blood Glucose / Cholesterol, LDL / Curcumin / Diabetes Mellitus, Type 2 / Double-Blind Method / Female / Gastrointestinal Absorption / Glucose Intolerance / Glycated Hemoglobin A / Humans / Japan / Lipoproteins, LDL / Male / Middle Aged / Time Factors / Treatment Outcome / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1155/2019/8208237 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31871950 ● Search Scopus @ Elsevier (PMID): 31871950 ● Search Scopus @ Elsevier (DOI): 10.1155/2019/8208237 (DOI: 10.1155/2019/8208237, PubMed: 31871950)
34.	Yoichi Sunagawa, Masafumi Funamoto, Shogo Sono, Kana Shimizu, Satoshi Shimizu, Mai Genpei, Yusuke Miyazaki, Yasufumi Katanasaka, Eriko Morimoto, Morio Ueno, Maki Komiyama, Hideaki Kakeya, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Curcumin and its demethoxy derivatives possess p300 HAT inhibitory activity and suppress hypertrophic responses in cardiomyocytes., Journal of Pharmacological Sciences, Vol.136, No.4, 212-217, 2018. (Keyword) Animals / Cattle / Cells, Cultured / Curcuma / Curcumin / Diarylheptanoids / Heart Failure / Humans / Hypertrophy / Myocytes, Cardiac / Phytotherapy / Rabbits / Structure-Activity Relationship / p300-CBP Transcription Factors (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jphs.2017.12.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29602708 ● Search Scopus @ Elsevier (PMID): 29602708 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jphs.2017.12.013 (DOI: 10.1016/j.jphs.2017.12.013, PubMed: 29602708)
35.	Yoichi Sunagawa, Nobuko Okamura, Yusuke Miyazaki, Kana Shimizu, Mai Genpei, Masafumi Funamoto, Satoshi Shimizu, Yasufumi Katanasaka, Eriko Morimoto, Hajime Yamakage, Maki Komiyama, Noriko Satoh-Asahara, Hiromichi Wada, Mika Suzuki, Koji Hasegawa and Tatsuya Morimoto : Effects of Products Containing Bacillus subtilis var. natto on Healthy Subjects with Neck and Shoulder Stiffness, a Double-Blind, Placebo-Controlled, Randomized Crossover Study., Biological & Pharmaceutical Bulletin, Vol.41, No.4, 504-509, 2018. (Keyword) Adult / Anti-Inflammatory Agents, Non-Steroidal / Arthralgia / Bacillus subtilis / Cross-Over Studies / Developed Countries / Double-Blind Method / Female / Fermented Foods / Headache / Humans / Japan / Male / Middle Aged / Myalgia / Neck / Pain Measurement / Severity of Illness Index / Shoulder / Skin Temperature / Soy Foods / Synbiotics (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b17-00780 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29415906 ● Search Scopus @ Elsevier (PMID): 29415906 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b17-00780 (DOI: 10.1248/bpb.b17-00780, PubMed: 29415906)
36.	Yusuke Miyazaki, Yasufumi Katanasaka, Yoichi Sunagawa, Sae Hirano-Sunagawa, Masafumi Funamoto, Eriko Morimoto, Maki Komiyama, Akira Shimatsu, Noriko Satoh-Asahara, Hajime Yamakage, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Effect of statins on atherogenic serum amyloid A and α1-antitrypsin low-density lipoprotein complexes., International Journal of Cardiology, Vol.225, 332-336, 2016. (Keyword) Adult / Aged / Aged, 80 and over / Atherosclerosis / Biomarkers / Dyslipidemias / Female / Follow-Up Studies / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Lipoproteins, LDL / Male / Middle Aged / Quinolines / Rosuvastatin Calcium / Serum Amyloid A Protein / Treatment Outcome / Ventricular Dysfunction, Left / alpha 1-Antitrypsin (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijcard.2016.09.116 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27756037 ● Search Scopus @ Elsevier (PMID): 27756037 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijcard.2016.09.116 (DOI: 10.1016/j.ijcard.2016.09.116, PubMed: 27756037)
37.	Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Yusuke Miyazaki, Atsushi Imaizumi, Hideaki Kakeya, Hajime Yamakage, Noriko Satoh-Asahara, Maki Komiyama, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD., International Journal of Chronic Obstructive Pulmonary Disease, Vol.11, 2029-2034, 2016. (Keyword) Administration, Oral / Adult / Aged / Aged, 80 and over / Anti-Inflammatory Agents / Atherosclerosis / Biological Availability / Biomarkers / Curcumin / Double-Blind Method / Down-Regulation / Drug Administration Schedule / Drug Compounding / Female / Gastrointestinal Absorption / Humans / Japan / Lipoproteins, LDL / Male / Middle Aged / Pulmonary Disease, Chronic Obstructive / Time Factors / Treatment Outcome / Young Adult / alpha 1-Antitrypsin (Link to Publication Site) ● Publication site (DOI): 10.2147/COPD.S104490 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27616885 ● Search Scopus @ Elsevier (PMID): 27616885 ● Search Scopus @ Elsevier (DOI): 10.2147/COPD.S104490 (DOI: 10.2147/COPD.S104490, PubMed: 27616885)
38.	Hidetoshi Suzuki, Yasufumi Katanasaka, Yoichi Sunagawa, Yusuke Miyazaki, Masafumi Funamoto, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Tyrosine phosphorylation of RACK1 triggers cardiomyocyte hypertrophy by regulating the interaction between p300 and GATA4., Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Vol.1862, No.9, 1544-1557, 2016. (Keyword) Angiotensin II Type 1 Receptor Blockers / Animals / Benzimidazoles / Biphenyl Compounds / Cardiomegaly / Cell Enlargement / Cells, Cultured / Disease Models, Animal / E1A-Associated p300 Protein / GATA4 Transcription Factor / Gene Knockdown Techniques / HEK293 Cells / Humans / Male / Myocytes, Cardiac / Neoplasm Proteins / Phenylephrine / Phosphorylation / Protein Binding / Rats / Rats, Inbred Dahl / Receptors for Activated C Kinase / Tetrazoles / Transcription, Genetic / Tyrosine (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbadis.2016.05.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27208796 ● Search Scopus @ Elsevier (PMID): 27208796 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbadis.2016.05.006 (DOI: 10.1016/j.bbadis.2016.05.006, PubMed: 27208796)
39.	Yoichi Sunagawa, Sae Hirano, Yasufumi Katanasaka, Yusuke Miyazaki, Masafumi Funamoto, Nobuko Okamura, Yuya Hojo, Hidetoshi Suzuki, Osamu Doi, Tsunehiro Yokoji, Eriko Morimoto, Tsukasa Takashi, Hitomi Ozawa, Atsushi Imaizumi, Morio Ueno, Hideaki Kakeya, Akira Shimatsu, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study., Journal of Nutritional Science and Vitaminology, Vol.61, No.1, 37-44, 2015. (Keyword) Administration, Oral / Adult / Area Under Curve / Biological Availability / Capsules / Colloids / Cross-Over Studies / Curcuma / Curcumin / Dose-Response Relationship, Drug / Double-Blind Method / Drug Delivery Systems / Female / Humans / Intestinal Absorption / Male / Particle Size / Phytotherapy / Plant Extracts / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.3177/jnsv.61.37 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25994138 ● Search Scopus @ Elsevier (PMID): 25994138 ● Search Scopus @ Elsevier (DOI): 10.3177/jnsv.61.37 (DOI: 10.3177/jnsv.61.37, PubMed: 25994138)
40.	Tatsuya Morimoto, Yasufumi Katanasaka, Yoichi Sunagawa, Sae Hirano, Yusuke Miyazaki, Masafumi Funamoto, Yuya Hojo, Hidetoshi Suzuki, Eriko Morimoto, Morio Ueno, Akira Shimatsu, Noriko Satoh-Asahara, Hajime Yamakage, Hiromichi Wada and Koji Hasegawa : Effects of Statins on Left Ventricular Diastolic Function in Patients with Dyslipidemia and Diastolic Dysfunction (Stat-LVDF Study)., Biological & Pharmaceutical Bulletin, Vol.38, No.9, 1404-1409, 2015. (Keyword) Aged / Diastole / Dyslipidemias / Female / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Male / Middle Aged / Quinolines / Rosuvastatin Calcium / Ventricular Dysfunction, Left / Ventricular Function, Left (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b15-00126 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26328497 ● Search Scopus @ Elsevier (PMID): 26328497 ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b15-00126 (DOI: 10.1248/bpb.b15-00126, PubMed: 26328497)
41.	Yoichi Sunagawa, Shogo Sono, Yasufumi Katanasaka, Masafumi Funamoto, Sae Hirano, Yusuke Miyazaki, Yuya Hojo, Hidetoshi Suzuki, Eriko Morimoto, Akira Marui, Ryuzo Sakata, Morio Ueno, Hideaki Kakeya, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Optimal dose-setting study of curcumin for improvement of left ventricular systolic function after myocardial infarction in rats., Journal of Pharmacological Sciences, Vol.126, No.4, 329-336, 2014. (Keyword) Animals / Curcumin / Disease Models, Animal / Dose-Response Relationship, Drug / Enzyme Inhibitors / Heart Failure / Male / Myocardial Infarction / Myocytes, Cardiac / Rats, Sprague-Dawley / Severity of Illness Index / Systole / Treatment Outcome / Ventricular Function, Left / p300-CBP Transcription Factors (Link to Publication Site) ● Publication site (DOI): 10.1254/jphs.14151FP (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25409899 ● Search Scopus @ Elsevier (PMID): 25409899 ● Search Scopus @ Elsevier (DOI): 10.1254/jphs.14151FP (DOI: 10.1254/jphs.14151FP, PubMed: 25409899)

Review, Commentary:

1.	Yasumasa Ikeda, Masafumi Funamoto and 山本みずほ : 腎性貧血の新規治療標的ヘプシジンとエリスロフェロン(今この研究が面白い!2024年9月増大号), 臨床雑誌内科, Vol.134, No.3, 788-791, Sep. 2024.
2.	Yasumasa Ikeda and Masafumi Funamoto : [A new attempt of integrated practice of basic medicine in Tokushima University]., Folia Pharmacologica Japonica, Vol.158, No.6, 440-443, Nov. 2023. (Summary) The Japan Accreditation Council for Medical Education has strengthened the promotion of horizontal and vertical integration of medical education, assuring the quality of medical education in Japan from an international perspective. Pharmacology plays an important role as a central hub that connects basic medical education with clinical medical education. As part of promoting horizontal integration of medical education, Tokushima University has started a joint practice with three basic medical subjects such as Biochemistry, Physiology, and Pharmacology for 2nd grade medical students in 2019. Each subject is in charge of two or four items of practice, and a total 8 of items are performed for 10 days in integrated practice every year. This joint practice has become an official subject in 2022. We introduce our experiences of unique practices based on their advantages and limitations. (Keyword) Humans / Universities / Education, Medical / Japan (Link to Publication Site) ● Publication site (DOI): 10.1254/fpj.23017 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37914318 ● Search Scopus @ Elsevier (PMID): 37914318 ● Search Scopus @ Elsevier (DOI): 10.1254/fpj.23017 (DOI: 10.1254/fpj.23017, PubMed: 37914318)
3.	Masafumi Funamoto and Yasumasa Ikeda : The association between COVID-19 and cardiovascular diseases, Shikoku Acta Medica, Vol.79, No.1,2, 37-42, Jun. 2023. (Keyword) COVID-19 / cardiovascular disease / cytokine storm / herbal medicines (Tokushima University Institutional Repository) ● Metadata: 118415 (Link to Publication Site) ● Publication site (DOI): 10.57444/shikokuactamedica.79.1.2_37 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390015191534393344 ● Search Scopus @ Elsevier (DOI): 10.57444/shikokuactamedica.79.1.2_37 (Tokushima University Institutional Repository: 118415, DOI: 10.57444/shikokuactamedica.79.1.2_37, CiNii: 1390015191534393344)
4.	Masafumi Funamoto, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : Roles of histone acetylation sites in cardiac hypertrophy and heart failure., Frontiers in Cardiovascular Medicine, Vol.10, Mar. 2023. (Summary) Heart failure results from various physiological and pathological stimuli that lead to cardiac hypertrophy. This pathological process is common in several cardiovascular diseases and ultimately leads to heart failure. The development of cardiac hypertrophy and heart failure involves reprogramming of gene expression, a process that is highly dependent on epigenetic regulation. Histone acetylation is dynamically regulated by cardiac stress. Histone acetyltransferases play an important role in epigenetic remodeling in cardiac hypertrophy and heart failure. The regulation of histone acetyltransferases serves as a bridge between signal transduction and downstream gene reprogramming. Investigating the changes in histone acetyltransferases and histone modification sites in cardiac hypertrophy and heart failure will provide new therapeutic strategies to treat these diseases. This review summarizes the association of histone acetylation sites and histone acetylases with cardiac hypertrophy and heart failure, with emphasis on histone acetylation sites. (Link to Publication Site) ● Publication site (DOI): 10.3389/fcvm.2023.1133611 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37008337 ● Search Scopus @ Elsevier (PMID): 37008337 ● Search Scopus @ Elsevier (DOI): 10.3389/fcvm.2023.1133611 (DOI: 10.3389/fcvm.2023.1133611, PubMed: 37008337)
5.	Yasumasa Ikeda, Masafumi Funamoto and Koichiro Tsuchiya : The role of iron in obesity and diabetes., The Journal of Medical Investigation : JMI, Vol.69, No.1.2, 1-7, Apr. 2022. (Summary) Iron is an essential trace metal for all life, but excess iron causes oxidative stress through catalyzing the toxic hydroxy-radical production via the Fenton reaction. The number of patients with obesity and diabetes has been increasing worldwide, and their onset and development are affected by diet. In both clinical and experimental studies, a high body iron content was associated with obesity and diabetes, and the reduction of body iron content to an appropriate level can ameliorate the status and development of obesity and diabetes. Macrophages play an essential role in the pathophysiology of obesity and diabetes, and in the metabolism and homeostasis of iron in the body. Recent studies demonstrated that macrophage polarization is related to adipocyte hypertrophy and insulin resistance through their capabilities of iron handling. Control of iron in macrophages is a potential therapeutic strategy for obesity and diabetes. J. Med. Invest. 69 : 1-7, February, 2022. (Keyword) Adipose Tissue / Diabetes Mellitus / Humans / Insulin Resistance / Iron / Macrophages / obesity (Tokushima University Institutional Repository) ● Metadata: 116403 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466128 ● Search Scopus @ Elsevier (PMID): 35466128 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.1 (Tokushima University Institutional Repository: 116403, DOI: 10.2152/jmi.69.1, PubMed: 35466128)
6.	Kana Shimizu, Masafumi Funamoto, Yoichi Sunagawa, Satoshi Shimizu, Yasufumi Katanasaka, Yusuke Miyazaki, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Anti-inflammatory Action of Curcumin and Its Use in the Treatment of Lifestyle-related Diseases., European Cardiology, Vol.14, No.2, 117-122, Jul. 2019. (Link to Publication Site) ● Publication site (DOI): 10.15420/ecr.2019.17.2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31360234 ● Search Scopus @ Elsevier (PMID): 31360234 ● Search Scopus @ Elsevier (DOI): 10.15420/ecr.2019.17.2 (DOI: 10.15420/ecr.2019.17.2, PubMed: 31360234)
7.	Tatsuya Morimoto, Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Yusuke Miyazaki and Koji Hasegawa : [Noble Heart Failure Therapy Using Food Compositions]., Journal of the Pharmaceutical Society of Japan, Vol.138, No.10, 1263-1269, 2018. (Keyword) Administration, Oral / Animals / Biological Availability / Curcumin / Diabetes Mellitus, Type 2 / Disease Models, Animal / Drug Compounding / heart failure / Humans / Life Style / Nanoparticles / Nanotechnology / Phytotherapy / Pulmonary Disease, Chronic Obstructive / Rats / Solubility (Link to Publication Site) ● Publication site (DOI): 10.1248/yakushi.18-00091-2 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30270270 ● Search Scopus @ Elsevier (PMID): 30270270 ● Search Scopus @ Elsevier (DOI): 10.1248/yakushi.18-00091-2 (DOI: 10.1248/yakushi.18-00091-2, PubMed: 30270270)

Proceeding of International Conference:

1.	Amiho Muramatsu, Masafumi Funamoto, Miyako Ueno, Masaki Imanishi, Yasumasa Ikeda and Koichiro Tsuchiya : Kampo medicine, orengedokuto, suppresses Doxorubicin-induced cardiotoxicity, 28th International Society of Cardiovascular Pharmacotherapy Annual Scientific Meeting, Nov. 2023.
2.	Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Toru Kato, Yoichi Ajiro, Maki Komiyama, Masaharu Akao, Hajime Yamakage, Noriko Satoh-Asahara, Hiromichi Wada, Yasumasa Ikeda, Tatsuya Morimoto and Koji Hasegawa : Effects of high-absorption curcumin for the prevention of hypertensive heart disease, 28th International Society of Cardiovascular Pharmacotherapy Annual Scientific Meeting, Nov. 2023.
3.	Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Maki Komiyama, Masaharu Akao, Akihiro Yasoda, Hajime Yamakage, Noriko Satoh-Asahara, Hiromichi Wada, Yasumasa Ikeda, Tatsuya Morimoto and Koji Hasegawa : Clinical trial for high-absorption curcumin, targeting p300-histonetransferase activity, in patients with hypertensive heart disease, 27TH ASIAN PACIFIC SOCIETY OF CARDIOLOGY CONGRESS, Jul. 2023.
4.	Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Hajime Yamakage, Noriko Satoh-Asahara, Maki Komiyama, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : High absorption curcumin reduces serum atherosclerotic low density lipoprotein levels in patients with mild COPD, 27TH ASIAN PACIFIC SOCIETY OF CARDIOLOGY CONGRESS, Jul. 2023.
5.	Yuto Kawase, Kana Shimizu, Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Yusuke Miyazaki, Satoshi Shimizu, Koji Hasegawa and Tatuya Morimoto : Young Investigator Award: Compound A, a Ginger Extract, Significantly Reduces Pressure Overload-induced Systolic Heart Failure in Mice., European Cardiology, Vol.16, e57, Dec. 2021. (Link to Publication Site) ● Publication site (DOI): 10.15420/ecr.2021.16.PO1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35106073 ● Search Scopus @ Elsevier (PMID): 35106073 ● Search Scopus @ Elsevier (DOI): 10.15420/ecr.2021.16.PO1 (DOI: 10.15420/ecr.2021.16.PO1, PubMed: 35106073)
6.	Satoshi Shimizu, Miho Yamada, Takahiro Katagiri, Yoichi Sunagawa, Yasufumi Katanasaka, Yusuke Miyazaki, Masafumi Funamoto, Sari Nurmila, Kana Shimizu, Naohisa Ogo, Akira Asai, Koji Hasegawa and Tatsuya Morimoto : Discovery of Novel Small Molecules for Heart Failure Therapy Using Cultured Cardiomyocyte by High Throughput Screening Assay., European Cardiology, Vol.16, e66, Dec. 2021. (Link to Publication Site) ● Publication site (DOI): 10.15420/ecr.2021.16.PO10 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35106082 ● Search Scopus @ Elsevier (PMID): 35106082 ● Search Scopus @ Elsevier (DOI): 10.15420/ecr.2021.16.PO10 (DOI: 10.15420/ecr.2021.16.PO10, PubMed: 35106082)
7.	Yoichi Sunagawa, Ayumi Katayama, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Yasufumi Katanasaka, Yusuke Miyazaki, Koji Hasegawa and Tatsuya Morimoto : The Polyunsaturated Fatty Acids EPA and DHA Prevent Myocardial Infarction-induced Heart Failure by Inhibiting p300-HAT Activity in Rats., European Cardiology, Vol.16, e68, Dec. 2021. (Link to Publication Site) ● Publication site (DOI): 10.15420/ecr.2021.16.PO12 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35106084 ● Search Scopus @ Elsevier (PMID): 35106084 ● Search Scopus @ Elsevier (DOI): 10.15420/ecr.2021.16.PO12 (DOI: 10.15420/ecr.2021.16.PO12, PubMed: 35106084)
8.	Hidemichi Takai, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Satoshi Shimizu, Yasufumi Katanasaka, Yusuke Miyazaki, Atsusi Imaizumi, Tadashi Hashimoto, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : A Novel Curcumin Formulation, ASD-Cur, Suppressed the Development of Systolic Dysfunction After Myocardial Infarction in Rats., European Cardiology, Vol.16, e69, Dec. 2021. (Link to Publication Site) ● Publication site (DOI): 10.15420/ecr.2021.16.PO13 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35106085 ● Search Scopus @ Elsevier (PMID): 35106085 ● Search Scopus @ Elsevier (DOI): 10.15420/ecr.2021.16.PO13 (DOI: 10.15420/ecr.2021.16.PO13, PubMed: 35106085)
9.	Mai Genpei, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Yusuke Miyazaki, Yasufumi Katanasaka, Nobuaki Takahashi, Hideaki Kakeya, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Erratum to: The Inhibitory Effects of Crucumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes., European Cardiology, Vol.13, No.2, 136, Dec. 2018. (Link to Publication Site) ● Publication site (DOI): 10.15420/ecr.2018.13.2.ER1 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30697358 ● Search Scopus @ Elsevier (PMID): 30697358 ● Search Scopus @ Elsevier (DOI): 10.15420/ecr.2018.13.2.ER1 (DOI: 10.15420/ecr.2018.13.2.ER1, PubMed: 30697358)
10.	Yoichi Sunagawa, Masafumi Funamoto, Anna Suzuki, Kana Shimizu, Ryoga Sakurai, Yasufumi Katanasaka, Yusuke Miyazaki, Tomohiro Asakawa, Toshiyuki Kan, Junya Inagaki, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : A Novel Target Molecule of Nobiletin Derived from Citrus Peels has a Therapeutic Potency Against the Development of Heart Failure., European Cardiology, Vol.12, No.2, 105, Dec. 2017. (Link to Publication Site) ● Publication site (DOI): 10.15420/ecr.2017:23:14 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30416575 ● Search Scopus @ Elsevier (PMID): 30416575 ● Search Scopus @ Elsevier (DOI): 10.15420/ecr.2017:23:14 (DOI: 10.15420/ecr.2017:23:14, PubMed: 30416575)
11.	Kana Shimizu, Masafumi Funamoto, Mai Genpei, Yoichi Sunagawa, Yasufumi Katanasaka, Yusuke Miyazaki, Hiroyuki Shibata, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : Curcumin Analogue GO-Y030 Significantly Improves Pressure Overload-induced Heart Failure in Vivo., European Cardiology, Vol.12, No.2, 106, Dec. 2017. (Link to Publication Site) ● Publication site (DOI): 10.15420/ecr.2017:23:15 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30416576 ● Search Scopus @ Elsevier (PMID): 30416576 ● Search Scopus @ Elsevier (DOI): 10.15420/ecr.2017:23:15 (DOI: 10.15420/ecr.2017:23:15, PubMed: 30416576)
12.	Mai Genpei, Yoichi Sunagawa, Masafumi Funamoto, Kana Shimizu, Yusuke Miyazaki, Yasufumi Katanasaka, Nobuaki Takahashi, Hideaki Kakeya, Hiromichi Wada, Koji Hasegawa and Tatsuya Morimoto : The Inhibitory Effects of Crucumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes., European Cardiology, Vol.12, No.2, 107, Dec. 2017. (Link to Publication Site) ● Publication site (DOI): 10.15420/ecr.2017:23:16 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30416577 ● Search Scopus @ Elsevier (PMID): 30416577 ● Search Scopus @ Elsevier (DOI): 10.15420/ecr.2017:23:16 (DOI: 10.15420/ecr.2017:23:16, PubMed: 30416577)

Proceeding of Domestic Conference:

1.	Masafumi Funamoto, Amiho Muramatsu, YAMAMOTO Mizuho, Shunji Hirose, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : 黄連解毒湯によるドキソルビシン誘導性心毒性に対する効果検討, 第8回黒潮カンファレンス, Sep. 2024.
2.	YAMAMOTO Mizuho, Masafumi Funamoto, 上原渉, 眞鍋智弘, 砂川陽一, 刀坂泰史, 浜辺俊秀, 川瀬裕斗, 鳴田竜也, 小見山麻紀, 長谷川浩二, Yasumasa Ikeda and 森本達也 : p300/CBPのヒストンアセチル化酵素活性を阻害する低分子化合物であるA485は圧負荷による収縮機能低下を改善した, 第8回黒潮カンファレンス, Sep. 2024.
3.	Shunji Hirose, Masafumi Funamoto, YAMAMOTO Mizuho, Masaki Imanishi, Yasumasa Ikeda and Koichiro Tsuchiya : 糖尿病性心筋症に対する漢方薬五苓散の抑制効果, 第8回黒潮カンファレンス, Sep. 2024.
4.	前田莉沙, 片桐宇大, 清水聡, Masafumi Funamoto, 浜辺俊秀, 砂川陽一, 川瀬裕斗, 鳴田竜也, 刀坂泰史, 長谷川浩二 and 森本達也 : High throughput screening assayにより同定したRFN-409は圧負荷による心肥大と左室収縮能低下を抑制した, 第9回日本心血管協会(JCVA)学術集会, 58, May 2024.
5.	中西俊輔, 高井秀通, 砂川陽一, Masafumi Funamoto, 川瀬裕斗, 鳴田竜也, 刀坂泰史, 浜辺俊秀, 今泉厚, Yasumasa Ikeda, 橋本正, 長谷川浩二 and 森本達也 : 新規クルクミン製剤であるcurcuRougeTMは心筋梗塞モデルラットにおいて心収縮能の低下を抑制した, 第9回日本心血管協会(JCVA)学術集会, 60, May 2024.
6.	眞鍋智弘, 上原渉, Masafumi Funamoto, 山本みずほ, 砂川陽一, 刀坂泰史, 浜辺俊秀, 川瀬裕斗, 鳴田竜也, Yasumasa Ikeda, 長谷川浩二 and 森本達也 : 圧負荷心不全モデルマウスにおいてBRG1阻害剤PFI-3は心収縮機能悪化を改善した, 第9回日本心血管協会(JCVA)学術集会, 61, May 2024.
7.	稲井恭子, 岩清水苑夏, 望月沙穂, 槌谷佳那子, 小野雅也, 砂川陽一, Masafumi Funamoto, 川瀬裕斗, 鳴田竜也, 刀坂泰史, 浜辺俊英, 小見山麻紀, 長谷川浩二, 坂本多穂, 黒川洵子 and 森本達也 : ノビレチンはドキソルビシン誘発心毒性に対する保護効果を示した, 第9回日本心血管協会(JCVA)学術集会, 63, May 2024.
8.	品川統也, 平子裕太, 清水果奈, Masafumi Funamoto, 川瀬裕斗, 鳴田竜也, 砂川陽一, 刀坂泰史, 浜辺俊英, 清水聡, 柴田浩行, 小見山麻紀, 長谷川浩二 and 森本達也 : クルクミン誘導体GO-Y022はクルクミンより低用量でマウスの圧負荷心不全を改善する, 第9回日本心血管協会(JCVA)学術集会, 67, May 2024.
9.	峯岸龍志, 砂川陽一, 石間彩花, 鈴木悠斗, 浜辺俊英, 刀坂泰史, Masafumi Funamoto, 清水聡, 長谷川浩二 and 森本達也 : 線維芽細胞特異的p300-BP1KOマウスは圧負荷による心線維化及び心筋肥大を抑制した, 第9回日本心血管協会(JCVA)学術集会, 67, May 2024.
10.	須藤優, 塚部凌輔, 川瀬裕斗, 清水聡, 浜辺俊英, 砂川陽一, Masafumi Funamoto, 清水果奈, 鳴田竜也, 刀坂泰史, 長谷川浩二 and 森本達也 : 転写因子GATA4の二量体形成が心筋細胞肥大反応を制御する, 第9回日本心血管協会(JCVA)学術集会, 68, May 2024.
11.	髙橋寧音, 川瀬裕斗, 平子裕太, 砂川陽一, 浜辺俊英, 刀坂泰史, 鳴田竜也, Masafumi Funamoto, 小見山麻紀, 長谷川浩二 and 森本達也 : 天然物サンショウ抽出物Compound Xは圧負荷による心筋肥大や心機能低下を改善させた, 第9回日本心血管協会(JCVA)学術集会, 68, May 2024.
12.	鈴木悠斗, 砂川陽一, Masafumi Funamoto, 石間彩花, 川瀬裕斗, 浜辺俊英, 刀坂泰史, Masafumi Funamoto, 清水聡, 長谷川浩二 and 森本達也 : 心臓特異的p300-BP1ノックアウトは圧負荷による心筋肥大及び心不全の進展を軽減させた, 第9回日本心血管協会(JCVA)学術集会, 69, May 2024.
13.	坂侑子, 砂川陽一, Masafumi Funamoto, 前川達也, 川瀬裕斗, 鳴田竜也, 浜辺俊英, 刀坂泰史, 長谷川浩二 and 森本達也 : オオイタドリ若芽エキスは心筋梗塞後の心不全の進展を抑制した, 第9回日本心血管協会(JCVA)学術集会, 70, May 2024.
14.	川瀬裕斗, 清水果奈, Masafumi Funamoto, 砂川陽一, 刀坂泰史, 浜辺俊英, 清水聡, 鳴田竜也, 小見山麻紀, 長谷川浩二 and 森本達也 : 圧負荷心不全モデルマウスにおいて，ショウガ抽出物である6-shogaolは心不全の進行を抑制した, 第9回日本心血管協会(JCVA)学術集会, 70, May 2024.
15.	色川雄大, 砂川陽一, 山田美帆, 片桐宇大, 前川健也, 清水聡, 刀坂泰史, 浜辺俊英, 川瀬裕斗, 鳴田竜也, Masafumi Funamoto, 清水果奈, 浅川倫宏, 長谷川浩二 and 森本達也 : ヒスチジン含有ペプチドであるアンセリンはp300-HAT活性阻害により，心筋細胞肥大および圧負荷モデルマウスの心収縮能低下を抑制した, 第9回日本心血管協会(JCVA)学術集会, 71, May 2024.
16.	Mizuho Yamamoto, Masafumi Funamoto, 上原渉, 眞鍋智弘, 砂川陽一, 刀坂泰史, 浜辺俊秀, 川瀬裕斗, 鳴田竜也, 小見山麻紀, 長谷川浩二, Yasumasa Ikeda and 森本達也 : 低分子化合物A485はp300-HAT阻害作用により圧負荷心不全モデルマウスの心不全悪化を抑制した, 第9回日本心血管協会(JCVA)学術集会, 71, May 2024.
17.	Masafumi Funamoto, Amiho Muramatsu, Masaki Imanishi, Hidenori Yasuda, Koichiro Tsuchiya and Yasumasa Ikeda : アントラサイクリン系抗がん剤による心毒性に対する黄連解毒湯の検討, 第9回日本心血管協会(JCVA)学術集会, 72, May 2024.
18.	Shunji Hirose, Masafumi Funamoto, Hidenori Yasuda, Masaki Imanishi, Yasumasa Ikeda and Koichiro Tsuchiya : 糖尿病合併心不全に対する漢方薬五苓散の抑制効果, 第144回日本薬理学会近畿部会, Mar. 2024.
19.	Yasumasa Ikeda, Masafumi Funamoto, Hidenori Yasuda, Masaki Imanishi and Koichiro Tsuchiya : 低重力下における消化管と骨髄における鉄動態の検討, 第144回日本薬理学会近畿部会, Mar. 2024.
20.	Masafumi Funamoto, Amiho Muramatsu, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : ドキソルビシン誘導性心毒性を抑制する漢方薬と作用機序の解明, 第53回日本心脈管作動物質学会, Feb. 2024.
21.	Masaki Imanishi, Takahisa Inoue, Keijo Fukushima, GOMI Yoshiki, HIGAKI Yoshiya, Masataka Nojima, Kohsuke Kondoh, SAWAMURA Takaya, Ryosuke Yamashita, Ryo Nakayama, Honoka Tsunematsu, GOTOH Kohei, Licht Miyamoto, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya : TCGAがんゲノムビッグデータによる膵がん悪性化因子の網羅的探索と腫瘍血管新生の寄与についての検討, 第53回日本心脈管作動物質学会年会, Feb. 2024.
22.	色川雄大, 砂川陽一, 山田美帆, 片桐宇大, 前川健也, 清水聡史, 刀坂泰史, 浜辺俊秀, 川瀬裕斗, 鳴田竜也, Masafumi Funamoto, 清水果奈, 浅川倫宏, 長谷川浩二 and 森本達也 : ヒスチジン含有ジペプチドであるアンセリンは心筋細胞肥大および圧負荷モデルマウスの心収縮能低下を抑制した, 第33回日本循環薬理学会, Jan. 2024.
23.	眞鍋智弘, 上原渉, Masafumi Funamoto, 山本みずほ, 砂川陽一, 刀坂泰史, 浜辺俊秀, 川瀬裕斗, 鳴田竜也, Yasumasa Ikeda, 長谷川浩二 and 森本達也 : 圧負荷心不全モデルマウスにおいて心収縮機能悪化をBRG1阻害剤 PFI-3は抑制した, 第33回循環薬理学会, Jan. 2024.
24.	髙橋寧音, 川瀬裕斗, 平子裕太, 鳴田竜也, Masafumi Funamoto, 砂川陽一, 刀坂泰史, 浜辺俊秀, 小見山麻紀, 長谷川浩二 and 森本達也 : 天然物サンショウの抽出物であるCompound Xは心機能低下を改善した, 第33回日本循環薬理学会, Jan. 2024.
25.	Masafumi Funamoto, Amiho Muramatsu, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : ドキソルビシン心毒性を抑制する漢方薬と作用機序の解明, 第33回日本循環薬理学会, Jan. 2024.
26.	Yasumasa Ikeda, SUENAGA Aoi, SETO Yasuyuki, Masafumi Funamoto, Masaki Imanishi and Koichiro Tsuchiya : 慢性腎臓病に対する漢方薬五苓散の効果の検討, 第97回日本薬理学会年会(神戸), Dec. 2023.
27.	Masafumi Funamoto, Amiho Muramatsu, Miyako Ueno, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : 漢方薬のドキソルビシン心毒性に対する効果の検討, 第97回日本薬理学会年会(神戸)2023年12月16日, Dec. 2023.
28.	Shunji Hirose, Masafumi Funamoto, Amiho Muramatsu, Miyako Ueno, Masaki Imanishi, Yasumasa Ikeda and Koichiro Tsuchiya : 糖尿病性心筋症におけるエピジェネティック制御機構, 第97回日本薬理学会年会(神戸), Dec. 2023.
29.	Masafumi Funamoto : 病的な心肥大におけるマクロファージ鉄ストレスによる心臓老化制御機構の解析, 日本心脈管作動物質学会若手研究者交流シンポジウム, Oct. 2023.
30.	Honoka Tsunematsu, Masaki Imanishi, Yuka Uemura, HIGAKI Yoshiya, Keijo Fukushima, Miyu Morisaki, Akari Katsura, Licht Miyamoto, Masafumi Funamoto, Yuya Horinouchi, Yasumasa Ikeda, Hiromichi Fujino, Koichi Tsuneyama and Koichiro Tsuchiya : 藍含有成分はendothelin-1発現を制御して肺動脈血管リモデリングを形成させる, 次世代を担う若手のための創薬・医療薬理シンポジウム2023, Aug. 2023.
31.	SAWAMURA Takaya, Masaki Imanishi, Keijo Fukushima, Ryosuke Yamashita, Kohsuke Kondoh, Ryo Nakayama, GOMI Yoshiki, Honoka Tsunematsu, Takahisa Inoue, GOTOH Kohei, Licht Miyamoto, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya : PARP阻害剤は低酸素環境下において生じる5-FU治療効果の減弱を回復させる, 生体機能と創薬シンポジウム2023, Aug. 2023.
32.	Natsuki Toyota, Masaki Imanishi, Takahisa Inoue, Honoka Tsunematsu, GOTOH Kohei, Licht Miyamoto, Masafumi Funamoto, Yasumasa Ikeda and Koichiro Tsuchiya : 亜硝酸塩が有するヒドロキシルラジカル消去活性の検討, 生体機能と創薬シンポジウム2023, Aug. 2023.
33.	GOMI Yoshiki, Masaki Imanishi, Takahisa Inoue, Keijo Fukushima, Ryosuke Yamashita, Ryo Nakayama, Masataka Nojima, Kohsuke Kondoh, SAWAMURA Takaya, Honoka Tsunematsu, GOTOH Kohei, Licht Miyamoto, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya : TCGAがんゲノムビッグデータとGEOトランスクリプトームデータとの統合解析による膵がん治療標的候補遺伝子の探索, 生体機能と創薬シンポジウム2023, Aug. 2023.
34.	Amiho Muramatsu, Masafumi Funamoto, Miyako Ueno, Masaki Imanishi, Yasumasa Ikeda and Koichiro Tsuchiya : ドキソルビシン心毒性に対する漢方薬効果の検討, 第7回黒潮カンファレンス(宮崎), Jul. 2023.
35.	Masafumi Funamoto, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : 病的心肥大と老化におけるマクロファージ鉄ストレスの役割の検討, ,第7回黒潮カンファレンス(宮崎), Jul. 2023.
36.	Amiho Muramatsu, Masafumi Funamoto, 上野実弥子, Masaki Imanishi, Yasumasa Ikeda and Koichiro Tsuchiya : 黄連解毒湯を用いたcGAS/STING/IRF3経路を介したドキソルビシン誘導性心毒性に対する検討, 第8回日本心血管協会(JCVA)学術集会(大分) 2023年6月10日, Jun. 2023.
37.	Masafumi Funamoto, Shunji Hirose, Amiho Muramatsu, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : 糖尿病性心筋症におけるエピジェネティックな老化制御機構の解明, 第8回日本心血管協会(JCVA)学術集会(大分), Jun. 2023.
38.	Kohsuke Kondoh, Masaki Imanishi, Ryosuke Yamashita, Keijo Fukushima, Ryo Nakayama, Honoka Tsunematsu, Takahisa Inoue, GOTOH Kohei, Licht Miyamoto, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya : 5-FUの膵がん細胞増殖抑制効果に対する低酸素―PARP活性化シグナルの役割, 第262回徳島医学会学術集会(徳島), Feb. 2023.
39.	Masafumi Funamoto : COVID-19と心疾患, 第266回徳島医学会学術集会, Feb. 2023.
40.	Shunji Hirose, Masafumi Funamoto, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : 2型糖尿病による心筋症モデルマウスの検討, 第262回徳島医学会学術集会, Feb. 2023.
41.	SETO Yasuyuki, Masafumi Funamoto and Yasumasa Ikeda : 黄連解毒湯を用いたドキソルビシン誘導性心毒性に対する検討, 第262回徳島医学会学術集会, Feb. 2023.
42.	Tatsuki Itoh, Masafumi Funamoto and Yasumasa Ikeda : 急性腎障害に対するマクロファージ鉄ストレスの役割の検討, 第262回徳島医学会学術集会, Feb. 2023.
43.	SUENAGA Aoi, Masafumi Funamoto and Yasumasa Ikeda : 慢性腎臓病に対する五苓散の効果, 第262回徳島医学会学術集会, Feb. 2023.
44.	Masaki Imanishi, 山下竜介, Keijo Fukushima, 近藤宏祐, 中山涼, 常松保乃加, 井上貴久, 後藤廣平, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya : 5-FU膵がん細胞増殖抑制効果に対する低酸素-PARPシグナルの役割, 第52回心脈管作動物質学会, Feb. 2023.
45.	Masafumi Funamoto, 砂川陽一, 刀坂泰史, 清水果奈, 長谷川浩二 and 森本達也 : 心不全の進展においてBRG1/p300複合体はH3K122のアセチル化を増加した, 第96回日本薬理学会年会, Nov. 2022.
46.	Yasumasa Ikeda, Masafumi Funamoto and Hiroyoshi Sei : New Attempt of Practice in Pharmacology Joint Practice with Basic Medical Departments in Tokushima University-, 第96回日本薬理学会年会教育企画シンボジウム, Nov. 2022.
47.	山下竜介, Masaki Imanishi, Keijo Fukushima, 近藤宏祐, 中山涼, 常松保乃加, 井上貴久, 後藤廣平, Masafumi Funamoto, Hiromichi Fujino, Yasumasa Ikeda and Koichiro Tsuchiya : 低酸素がん微小環境におけるPARP活性化は5-FUによる膵がん細胞増殖抑制効果の減弱に寄与する, 第142回日本薬理学会近畿部会, Nov. 2022.
48.	Masafumi Funamoto, 砂川陽一, 刀坂泰史, 清水果奈, 清水聡志, 長谷川浩二, Yasumasa Ikeda and 森本達也 : 心不全発症時におけるBRG1を介したヒストンのアセチル修飾部位の検討, 第51回日本心脈管作動物質学会, Jul. 2022.
49.	Yasumasa Ikeda and Masafumi Funamoto : 漢方薬の腎保作用の検討, 第51回日本心脈管作動物質学会, Jul. 2022.
50.	Masafumi Funamoto, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : ドキソルビシン誘導性心毒性に対するオウゴン成分オウゴニンの効果検討, 第141回日本薬理学会近畿部会, Jul. 2022.
51.	Tatsuki Itoh, Masafumi Funamoto, Masaki Imanishi, Koichiro Tsuchiya and Yasumasa Ikeda : 急性腎障害におけるマクロファージ鉄ストレスの役割の検討, 第141回日本薬理学会近畿部会, Jul. 2022.
52.	Masafumi Funamoto, Yoichi Sunagawa, Yasufumi Katanasaka, Kana Shimizu, Satoshi Shimizu, Koji Hasegawa, Yasumasa Ikeda and Tatsuya Morimoto : The Interaction of the p300 with the BRG1 Increases the Acetylation levels of the H3K122 in Heart Failure, 第95回日本薬理学会年会, Mar. 2022.
53.	Yasumasa Ikeda, Masafumi Funamoto, Masaki Imanishi and Koichiro Tsuchiya : 漢方薬の新規腎保護作用の検討, 第95回日本薬理学会年会, Mar. 2022.
54.	Masafumi Funamoto, 砂川陽一, 刀坂泰史, 清水果奈, 清水聡志, 長谷川浩二, Yasumasa Ikeda and 森本達也 : 心不全期にp300/BRG1複合体がH3K122のアセチル化レベルを増加させた, 第95回日本薬理学会年会, Mar. 2022.
55.	Masafumi Funamoto and Yasumasa Ikeda : 生薬由来化合物のオウゴニンによるドキソルビシンの心毒性に対する効果検討, 第31回日本循環薬理学会, Dec. 2021.
56.	Masafumi Funamoto and Yasumasa Ikeda : ドキソルビシンの心毒性に対する生薬由来化合物オウゴニンの効果検討, 第140回日本薬理学会近畿部会, Nov. 2021.
57.	Masafumi Funamoto, 砂川陽一, 刀坂泰史, 清水果奈, 宮崎雄輔, 清水聡史, 長谷川浩二, Yasumasa Ikeda and 森本達也 : 心肥大期から心不全期におけるヒストンのアセチル化修飾部位の検討, 第5回黒潮カンファレンス, Sep. 2021.
58.	Masafumi Funamoto, 砂川陽一, 刀坂泰史, 清水果奈, 宮崎雄輔, 清水聡史, 長谷川浩二, Yasumasa Ikeda and 森本達也 : 心不全発症時におけるヒストンのアセチル化修飾部位の検討, 第263回徳島医学会学術集会, Aug. 2021.
59.	Masafumi Funamoto, 砂川陽一, 刀坂泰史, 清水果奈, 宮崎雄輔, 清水聡史, 長谷川浩二, Yasumasa Ikeda and 森本達也 : 心不全発症におけるヒストンのアセチル化修飾部位の変化を介した転写制御機構の解明, 第28回市大フォーラム, Aug. 2021.

Et cetera, Workshop:

1.	Masafumi Funamoto : 糖尿病性心筋症における漢方薬の可能性, 第29回徳島kampo研究会, Feb. 2024.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

心不全関連遺伝子領域におけるエピジェネティックな転写制御機構の解明 (Project/Area Number: 22K16106 )
Elucidation of transcriptional regulatory mechanisms Involved in the development of heart failure with epigenetic changes (Project/Area Number: 20K22714 )
Analysis of epigenetic transcriptional regulatory mechanism in heart failure (Project/Area Number: 17J11509 )
Search by Researcher Number (40882064)

Associate Professor : Funamoto, Masafumi

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)